Navigation Links
AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
Date:10/15/2007

TUSTIN, Calif., Oct. 15 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), developer and marketer of tests for the early detection of cancer and other serious diseases, announced today that it has filed with the U.S. Food & Drug Administration (FDA) for clearance to market its unique, proprietary DR-70(R) (FDP) ELISA tumor marker test for use as an aid in monitoring patients previously diagnosed with colorectal cancer. AMDL used the guidance provided at the meeting they had with the FDA on January 25, 2007.

In its submission to the FDA, AMDL and its statistical consultant, Dr. Richard P. Chiacchierini of RPCA in Rockville, MD, have provided statistical evidence that the DR-70(R) (FDP) ELISA is an "informative test" to validate AMDL's claim that the DR-70(R) (FDP) ELISA is effective at monitoring colorectal cancer patients.

AMDL's DR-70(R) (FDP) ELISA is an in vitro diagnostic test for the DR-70(R) (FDP) antigen in human serum. When cleared to market by the FDA, it will be used as an aid in monitoring the disease status in patients who have been previously diagnosed with colorectal cancer. AMDL believes that the test will be useful as an aid in monitoring cancer patients throughout the course of the disease, including after primary surgery, and in determining the response to therapy.

"FDA clearance to market will be a major step for AMDL in the acceptance of DR-70(R) (FDP) for the monitoring of colorectal cancer, not only in the U.S. but worldwide. We have forwarded to the FDA the data that we believe will show the efficacy and safety of our test," said Gary L. Dreher, President and CEO.

About AMDL

More information about AMDL and its products can be obtained at http://www.amdl.com.

Forward-Looking Statements

Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.

Contact: AMDL, Inc.

Paul Knopick

AMDL Investor Relations

Direct Line: 949.707.5365

VoiceMail: 714.505.4460


'/>"/>
SOURCE AMDL, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Neurognostics receives special FDA clearance for MindState fDAD
2. Third Wave receives FDA clearance of pharmacogenetic test
3. GE Medical Systems Receives FDA Clearance for New MRI System
4. Reforming FDA: Focus on safety, let market judge efficacy
5. Internet-enabled niche markets take center stage
6. GE Healthcare leads compact ultrasound market
7. Tech upstart VoVision could disrupt the voice-recognition market
8. Corn prices and ethanol: Are the markets flaky - or working as they should?
9. TomoTherapy sees sustained market advantage
10. Can a talent market work inside organizations?
11. Risks and returns: Building a search engine marketing portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Fla. , Feb. 16, 2017  MDNA ... revolutionizing the development of liquid biopsy tests based ... entered into an exclusive license agreement with its ... MDNA,s proprietary liquid biopsy test for prostate cancer, ... South Korea . This is the first ...
(Date:2/16/2017)... Mass. , Feb. 16, 2017   Biostage, ... the "Company"), a biotechnology company developing bioengineered organ implants ... esophagus, bronchus and trachea, announced today the closing on ... of 20,000,000 shares of common stock and warrants to ... proceeds of $8.0 million. The offering was priced at ...
(Date:2/16/2017)... Feb. 16, 2017  Champions Oncology, Inc. (NASDAQ: ... and sale of advanced technology solutions and products to ... announced the addition of new cohorts of PDX models ... models will expand Champions, product line in hepatocellular cancer, ... cancer, AML, and non-small cell lung cancer (including EGFR ...
(Date:2/16/2017)... and NEW YORK , Feb. ... near completion of their $7M Series B financing, adding ... of the $3.5M led by Mesa Verde Venture Partners ... These resources will be directed towards further accelerating commercial ... a comprehensive genomic profiling test and expanding the Paradigm ...
Breaking Biology Technology:
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, ... clinical-stage immuno-oncology company specializing in the development of ... the treatment of cancer and metastatic disease, announced ... and GMP manufacturing of a second clinical lot ... targeting folate receptor alpha. The manufactured vaccine product ...
(Date:2/2/2017)... Feb. 1, 2017  Central to its deep ... advances worldwide, The Japan Prize Foundation today announced ... have pushed the envelope in their respective fields ... Three scientists are being recognized with the 2017 ... not only contribute to the advancement of science ...
(Date:1/31/2017)...  Spero Therapeutics, LLC, a biopharmaceutical company founded ... bacterial infections, today announced it has acquired a ... Bono Bio Ltd (PBB) to bolster its pipeline ... of Gram-negative bacteria.   The assets acquired have been ... group company. "The acquisition of these ...
Breaking Biology News(10 mins):